Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.
You may also be interested in...
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”